Climate Change Data Portal
DOI | 10.1177/0192623317749452 |
Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop | |
Lenz, B.1; Braendli-Baiocco, A.1; Engelhardt, J.2; Fant, P.3; Fischer, H.1; Francke, S.4; Fukuda, R.5; Groeters, S.6; Harada, T.7; Harleman, H.8; Kaufmann, W.9; Kustermann, S.1; Nolte, T.10; Palazzi, X.11; Pohlmeyer-Esch, G.10; Popp, A.12; Romeike, A.13; Schulte, A.14; Lima, B. Silva15; Tomlinson, L.11; Willard, J.16; Wood, C. E.17; Yoshida, M.18 | |
发表日期 | 2018-02-01 |
ISSN | 0192-6233 |
卷号 | 46期号:2页码:224-246 |
英文摘要 | Lysosomes have a central role in cellular catabolism, trafficking, and processing of foreign particles. Accumulation of endogenous and exogenous materials in lysosomes represents a common finding in nonclinical toxicity studies. Histologically, these accumulations often lack distinctive features indicative of lysosomal or cellular dysfunction, making it difficult to consistently interpret and assign adverse dose levels. To help address this issue, the European Society of Toxicologic Pathology organized a workshop where representative types of lysosomal accumulation induced by pharmaceuticals and environmental chemicals were presented and discussed. The expert working group agreed that the diversity of lysosomal accumulations requires a case-by-case weight-of-evidence approach and outlined several factors to consider in the adversity assessment, including location and type of cell affected, lysosomal contents, severity of the accumulation, and related pathological effects as evidence of cellular or organ dysfunction. Lysosomal accumulations associated with cytotoxicity, inflammation, or fibrosis were generally considered to be adverse, while those found in isolation (without morphologic or functional consequences) were not. Workshop examples highlighted the importance of thoroughly characterizing the biological context of lysosomal effects, including mechanistic data and functional in vitro readouts if available. The information provided here should facilitate greater consistency and transparency in the interpretation of lysosomal effects. |
英文关键词 | adversity;lysosomal accumulation;hazard;risk-benefit;risk assessment;phospholipidosis;PEGylated;antisense oligonucleotides;alpha-2u globulin;iron;lipofuscin |
语种 | 英语 |
WOS记录号 | WOS:000429969400011 |
来源期刊 | TOXICOLOGIC PATHOLOGY
![]() |
来源机构 | 美国环保署 |
文献类型 | 期刊论文 |
条目标识符 | http://gcip.llas.ac.cn/handle/2XKMVOVA/61886 |
作者单位 | 1.F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Pharmaceut Sci, Roche Innovat Ctr Basel, Grenzacherstr 124,Bldg 73-307, CH-4070 Basel, Switzerland; 2.Ionis Pharmaceut Inc, Carlsbad, CA USA; 3.Charles River Labs, Lyon, France; 4.US FDA, CFSAN, College Pk, MD USA; 5.Axcelead Drug Discovery Partners Inc, Fujisawa, Kanagawa, Japan; 6.BASF SE, Dept Expt Toxicol & Ecol, Ludwigshafen, Germany; 7.Inst Environm Toxicol, Ibaraki, Japan; 8.Fresenius Kabi Deutschland GmbH, Global Med Clin & Regulatory Affairs, Global Preclin Dev & Management, Bad Homburg, Germany; 9.Merck, Darmstadt, Germany; 10.Boehringer Ingelheim Pharma GmbH & Co KG, Nonclin Drug Safety Germany, Biberach, Germany; 11.Pfizer WRD, Global Pathol, DSRD, Groton, CT USA; 12.AbbVie, Global Preclin Safety, Ludwigshafen, Germany; 13.Covance Labs Inc, Rueil Malmaison, France; 14.German Fed Inst Risk Assessment, Dept Chem & Prod Safety, Berlin, Germany; 15.Univ Lisbon, Dept Pharmacol Sci, Fac Pharm, Lisbon, Portugal; 16.US FDA, CDER, Silver Spring, MD USA; 17.US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USA; 18.Food Safety Commiss, Cabinet Off, Tokyo, Japan |
推荐引用方式 GB/T 7714 | Lenz, B.,Braendli-Baiocco, A.,Engelhardt, J.,et al. Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop[J]. 美国环保署,2018,46(2):224-246. |
APA | Lenz, B..,Braendli-Baiocco, A..,Engelhardt, J..,Fant, P..,Fischer, H..,...&Yoshida, M..(2018).Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop.TOXICOLOGIC PATHOLOGY,46(2),224-246. |
MLA | Lenz, B.,et al."Characterizing Adversity of Lysosomal Accumulation in Nonclinical Toxicity Studies: Results from the 5th ESTP International Expert Workshop".TOXICOLOGIC PATHOLOGY 46.2(2018):224-246. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。